Flatiron Health shared a post on LinkedIn:
“Announced Today: We’re proud to share that Paradigm Health has acquired Flatiron Health’s Clinical Research Business, marking the start of a new strategic partnership designed to rebuild and modernize the clinical research ecosystem.
This collaboration brings together Flatiron’s trusted oncology research network and solutions with Paradigm’s AI-powered trial platform, uniting two organizations that, together, are poised to lead the industry in making trials more efficient, representative, and accessible. It represents exactly what Flatiron has been building toward over the past several years: positioning this work for long-term growth, greater investment, and broader impact.
As Flatiron enters this next chapter, we’ll continue to focus on our two core growth engines: Point of Care and Global Evidence—doubling down on the work that makes us a leader in real-world evidence, oncology data, and technology-enabled transformation.
This moment is also a reflection of the incredible strength of our Clinical Research team. Their expertise, rigor, and leadership have set a new standard that will only expand under this partnership.
We’re excited to partner with Paradigm Health, providers, and sponsors to bring the future of clinical research closer to every patient, and to accelerate the innovation that will define the next decade of cancer care.
Neal Meropol, Vice President of Research Oncology at Flatiron Health, shared this post, adding:
“It is so gratifying to witness the seeds of an idea – how to streamline the design and conduct of clinical trials to improve access for all cancer patients — develop into a flourishing business and now a new partnership to rapidly expand global impact!
Congrats to all my colleagues at Flatiron Health and Paradigm Health who made this happen!”
Kent Thoelke, CEO of Paradigm Health, shared a post on LinkedIn:
“I am thrilled to be able to announce that Today at Paradigm Health we shared two big steps forward towards achieving our mission of enabling scaled access to clinical trials for patients in Community and Rural healthcare systems :
- We’ve acquired Flatiron Health’s Clinical Research Business and formed a long-term strategic partnership with their team.
- We raised $78M in an oversubscribed Series B to help us scale what comes next.
This acquisition of the Flatiron Clinical Research Business and our work with Flatiron is especially meaningful to our vision and mission. Bringing together Paradigm Health’s end-to-end clinical trial platform and global network with Flatiron’s deeply rooted U.S. community oncology footprint creates something rare in this industry: a truly integrated, AI-enabled infrastructure for running faster, more inclusive clinical trials. It puts Paradigm Health in a position to build—at scale—the kind of system patients, providers and biopharma sponsors have needed for a long time.
The new funding also gives us the capacity to meet the increasing demand we’re already seeing from sponsors and health systems who want trials to be more efficient, more representative, and accessible in more places. It will help us grow across therapeutic areas and expand into geographies where access has been limited for far too long.
At the heart of all this is a simple truth: clinical trials are how we learn more about innovative medicines and therapies. But today, too many patients—especially those in community and rural settings—never get the chance to participate. Their perspectives don’t show up in the data, which slows down development, increases cost, and ultimately leaves gaps in the care they receive.
If we want research to reflect the people new therapies are meant to serve, we have to meet patients where they are. By expanding our provider network and scaling our platform across the U.S., we’re taking a major step toward that reality: trials that happen in real clinics, in real communities, for real patients.
I’m deeply grateful for the collaboration between the teams at Paradigm Health and Flatiron—and for Nathan Hubbard’s leadership at Flatiron in helping to bring this partnership to life. I’m excited about what we’re building: a stronger, more equitable clinical-trial infrastructure for the country.
Learn more about our acquisition and strategic partnership.
Read more about our Series B raise.”
Alan Watson, Director of Sponsor Success at Paradigm Health, also shared a post on LinkedIn, about this news:
“Proud moment for our team – Flatiron’s clinical research business is moving into its next chapter, now as integral members of the Paradigm Health team!
This collaboration brings more trial options close to the homes of millions of Americans, lessens administrative burden on trial coordinators, and makes executing trials faster for biopharma sponsors while ensuring higher-quality data.”
More posts featuring Paradigm Health.
